Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758159 | 0.91 | TP53 (0.37) | TP53KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL505777 | 0.87 | CA1 (0.50) | TP53KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL726216 | 0.81 | KDM4E (0.46) | TP53KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL18978867 | 0.81 | PDE4A (0.38) | ALDH1A1CYP3A4CA1CA2CA12 | |
| SCHEMBL357603 | 0.79 | GABRA1 (0.48) | KDM4EALDH1A1HPGDHSD17B10CA1 | |
| SCHEMBL695730 | 0.79 | CA1 (0.42) | TP53KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL2380969 | 0.79 | CA1 (0.42) | TP53KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL2424037 | 0.79 | TAAR1 (0.42) | TP53KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL1374548 | 0.79 | ALDH1A1 (0.56) | TP53KDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL11358137 | 0.79 | TP53 (0.59) | TP53KDM4EALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481827-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USE THEREOF | JEIL PHARMACEUTICAL CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| CN-109415362-B | Imidazo [1,2-a ] pyridine derivatives, process for their preparation and their use | 第一药品株式会社 | 2021-07-30 | — | — | CN | disclosed |
| CN-109265471-B | FXR receptor agonists | 轩竹生物科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-10875949-B2 | Polymerizable materials based on dimerizable benzaldehyde derivatives | IVOCLAR VIVADENT AG (LI) | 2020-12-29 | — | — | US | disclosed |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| EP-3481827-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USE THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018008929-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USE THEREOF | JEIL PHARMACEUTICAL CO.,LTD. (KR) | 2018-01-11 | — | — | WO | disclosed |
| US-9676728-B2 | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-13 | — | — | US | disclosed |
| US-9676728-B2 | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-13 | — | — | US | disclosed |
| EP-1752455-A2 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-7091217-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-08-15 | — | — | US | disclosed |
| EP-1317451-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006010965-A1 | INDOLE-2 -CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | TP53 2322/4885KDM4E 4775/4885ALDH1A1 1249/4885 |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | TP53 2322/4885KDM4E 4775/4885ALDH1A1 1249/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | TP53 2322/4885KDM4E 4775/4885ALDH1A1 1249/4885 |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | HRH2, GIPR, HRH4 | TP53 3468/4885KDM4E 3876/4885ALDH1A1 621/4885 |
| US-10875949-B2 | Polymerizable materials based on dimerizable benzaldehyde derivatives | FANCI, CAD, ALDH1A2 | TP53 2276/4885KDM4E 3042/4885ALDH1A1 25/4885 |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | GIPR, PGC, VIP | TP53 3246/4885KDM4E 4011/4885ALDH1A1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.